ZYME

+ Watchlist + Portfolio

Zymeworks Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $27.21
52-Week Range: $13.60 – $29.75
Market Cap: $1.89B
P/E (TTM): —
EPS (TTM): -2.02
Dividend Yield: —

Advanced Metrics

Price/Book: 23.62
PEG Ratio: —
Return on Equity: -72.31%
Return on Assets: -24.15%
Gross Margin: -246.66%
Operating Margin: -918.95%
Profit Margin: 0.00%
Current Ratio: 6.32
Debt/Equity: 0.20
Total Debt: $16.01M
Free Cash Flow: $-65.06M
Revenue Growth: -90.60%
Earnings Growth: —
Enterprise Value: $1.68B

ZYME Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$412.48M	$76.01M	$76.30M	$105.97M
Research & Development	$208.60M	$143.62M	$134.62M	$137.00M
Selling, General & Admin	$73.40M	$70.40M	$61.50M	$61.50M
Operating Expenses	$282.00M	$214.02M	$196.12M	$198.50M
Operating Income	$130.49M	-$138.01M	-$119.82M	-$92.53M
EBITDA	$142.49M	-$120.70M	-$108.62M	-$81.42M
Pretax Income	$135.23M	-$119.24M	-$116.61M	-$79.75M
Income Tax	$10.89M	-$568.00K	$6.08M	$1.38M
Net Income	$124.34M	-$118.67M	-$122.69M	-$81.13M
Diluted EPS	1.90	-1.72	-1.62	-1.08
Diluted Shares	65.25M	68.86M	75.88M	75.41M

ZYME Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$400.91M	$157.56M	$66.10M	$41.16M
Receivables	$33.40M	$19.48M	$55.81M	$4.64M
Current Assets	$544.71M	$412.93M	$300.45M	$248.77M
Total Assets	$648.73M	$580.88M	$463.09M	$346.53M
Current Liabilities	$95.63M	$55.76M	$88.29M	$42.32M
Total Debt	$28.11M	$26.72M	$18.51M	$18.27M
Total Liabilities	$155.77M	$116.07M	$124.32M	$78.03M
Retained Earnings	-$558.76M	-$677.44M	-$830.34M	-$953.16M
Shareholders' Equity	$492.96M	$464.81M	$338.77M	$268.50M
Working Capital	$449.08M	$357.16M	$212.16M	$206.45M

ZYME Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$144.11M	-$118.32M	-$110.06M	-$33.01M
Capital Expenditure	-$13.13M	-$4.08M	-$3.07M	-$2.35M
Free Cash Flow	$130.98M	-$122.40M	-$113.12M	-$35.36M
Depreciation & Amortisation	$12.00M	$17.30M	$11.19M	$11.11M
Stock-Based Compensation	$4.01M	$8.10M	$17.79M	$28.03M
Investing Cash Flow	-$53.85M	-$207.25M	$38.76M	$26.66M
Financing Cash Flow	$108.58M	$81.87M	-$20.44M	-$18.56M
Share Repurchases	$0.00	$0.00	-$30.05M	-$41.70M
Net Change in Cash	$198.84M	-$243.71M	-$91.74M	-$24.90M

ZYME Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$27.11M	$48.73M	$27.61M	$2.52M	$2.41M
Research & Development	$35.74M	$34.45M	$35.58M	$31.23M	$34.46M
Selling, General & Admin	$17.00M	$14.90M	$14.10M	$15.40M	$15.10M
Operating Expenses	$52.74M	$49.35M	$49.68M	$46.63M	$49.56M
Operating Income	-$25.63M	-$623.00K	-$22.06M	-$44.12M	-$47.15M
EBITDA	-$18.84M	$2.59M	-$19.48M	-$42.11M	-$41.44M
Pretax Income	-$22.14M	$2.13M	-$18.27M	-$41.48M	-$46.35M
Income Tax	$496.00K	-$186.00K	$1.34M	-$270.00K	-$2.19M
Net Income	-$22.64M	$2.32M	-$19.60M	-$41.21M	-$44.16M
Diluted EPS	-0.30	0.03	-0.26	-0.55	-0.59
Diluted Shares	75.23M	77.38M	75.78M	75.34M	74.69M

ZYME Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$76.20M	$98.25M	$64.83M	$41.16M	$244.28M
Receivables	$24.59M	$2.63M	$29.35M	$4.64M	$4.67M
Current Assets	$306.47M	$296.13M	$291.71M	$248.77M	$385.68M
Total Assets	$425.52M	$408.38M	$397.27M	$346.53M	$478.21M
Current Liabilities	$65.10M	$38.50M	$42.04M	$42.32M	$35.65M
Total Debt	$18.46M	$18.68M	$18.90M	$18.27M	$17.04M
Total Liabilities	$100.56M	$73.88M	$77.20M	$78.03M	$314.63M
Retained Earnings	-$852.97M	-$850.65M	-$886.47M	-$953.16M	-$1.07B
Shareholders' Equity	$324.97M	$334.51M	$320.06M	$268.50M	$163.59M
Working Capital	$241.36M	$257.63M	$249.67M	$206.45M	$350.03M

ZYME Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.41M	$12.07M	-$31.41M	-$10.26M	-$45.72M
Capital Expenditure	-$338.00K	-$884.00K	-$410.00K	-$720.00K	-$216.00K
Free Cash Flow	-$3.75M	$11.19M	-$31.82M	-$10.98M	-$45.93M
Depreciation & Amortisation	$3.31M	$3.21M	$2.58M	$2.01M	$2.85M
Stock-Based Compensation	$6.40M	$5.87M	$6.91M	$8.85M	$6.93M
Investing Cash Flow	$12.18M	$8.74M	$368.00K	$5.37M	$69.96M
Financing Cash Flow	$1.32M	$1.32M	-$2.45M	-$18.74M	$178.79M
Share Repurchases	$0.00	—	—	-$25.48M	-$76.15M
Net Change in Cash	$10.09M	$22.14M	-$33.50M	-$23.63M	$203.03M

Market Snapshot

About

Zymeworks is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics for cancer and other diseases. The company specializes in bispecific antibodies that can simultaneously engage two different targets, potentially offering improved efficacy over traditional antibody therapies. Zymeworks uses proprietary technology platforms to create differentiated therapeutic candidates.